Bavarian Nordic Announces Interim Results for the First Three Months of 2019

NEXT STORY
Centauri’s AlphamerTM Platform highlighted at 4th Annual Advances in Immuno-Oncology Congress
PREV STORY
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aduro Biotech to Present at JP Morgan Healthcare Conference

BERKELEY, Calif., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced ...

author_avatar
NASDAQ Market News

EyeGate Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update

WALTHAM, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or ...

author_avatar
NASDAQ Market News

Humanigen Appoints Rainer Boehm, M.D., to Board of Directors

BRISBANE, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company ...

author_avatar
NASDAQ Market News